<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><meta name="exporter-version" content="Evernote Mac 7.14 (458244)"/><meta name="author" content="taylor.arhar@gmail.com"/><meta name="created" content="2018-11-02 21:54:52 +0000"/><meta name="latitude" content="37.76903611111111"/><meta name="longitude" content="-122.3919444444444"/><meta name="source" content="desktop.mac"/><meta name="updated" content="2018-11-28 22:44:51 +0000"/><title>October 31, 2018</title></head><body><div>DJA221 and DJC17 purification day 2:</div><div>- see attached for details</div><div>- starting point: DJA221 and TEV mixture dialyzed into 1X his binding buffer; DJC17 diluted into 500mL 50mM Tris, 750mM NaCl, 30mM imidazole, 3% EtOH (labeled as wash 2)</div><div>- end point: SEC200 purified DJA221, in dilute fractions in JDP buffer (50mM Tris, 300mM NaCl); DJC17 in the above buffer, concentrated to approx 25mL</div><div>- DJA221 was successfully cleaved andÂ eluted in the FT, concentrated down to 10mL for two 5mL injections onto SEC200 column</div><div>- two major peaks were present, as described; major product in each peak was DJA221</div><div><img src="October%2031,%202018.html.resources/103118%20DJA221%20Tev%20cleavage.tif" /><br/></div><div><br/></div></body></html>
